Recurrent urinary tract infection: Stimulating immune response through vaccines as an alternative to antimicrobial prophylaxis

Abstract

Get full access to this article

View all access options for this article.

References

Anger

Lee

Ackerman

, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol Aug, 2019; 202: 282–289.

Foxman

Brown

. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am Jun, 2003; 17: 227–241.

Bonkat G

Bruyère

. EAU guidelines on urological infections. European Association of Urology. Eur Urol 2023; 2: 10–14.

Lorenzo-Gomez

Foley

Nickel

, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid Apr, 2022; 1: EVIDoa2100018.

Nickel

Doiron

. An effective sublingual vaccine, MV140, safely reduces risk of recurrent urinary tract infection in women. Pathogens Feb 21, 2023; 12: 359.

Nickel

Saz-Leal

Doiron

. Could sublingual vaccination be a viable option for the prevention of recurrent urinary tract infection in Canada? A systematic review of the current literature and plans for the future. Can Urol Assoc J Aug, 2020; 14: 281–287.

Prattley

Geraghty

Moore

, et al. Role of vaccines for recurrent urinary tract infections: a systematic review. Eur Urol Focus May 15, 2020; 6: 593–604.

Nestler

Peschel

Horstmann

, et al. Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac(R) in patients with recurrent symptomatic uncomplicated bacterial urinary tract infections. Int Urol Nephrol Jan, 2023; 55: 9–16.

Huttner

Hatz

van den Dobbelsteen

, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis May, 2017; 17: 528–537.